DreAMLand™ is a first-of-its-kind digital therapeutic to treat anxiety and depressive symptoms in adults with acute myeloid leukemia (AML) who are hospitalized for a regimen of high-intensity induction chemotherapy.
DreAMLand™ is intended to treat the anxiety and depressive symptoms created by the unique psychological stressors specific to adult patients with AML undergoing high-intensity induction chemotherapy (HIC). This on-demand digital therapeutic is intended to be used in the inpatient setting during the 4-6 weeks associated with HIC treatment. The content is synchronized with the HIC treatment regimen to blunt the unique psychological stressors endured by this subset of patients with AML and is therefore not applicable to patients with AML undergoing outpatient treatment.
In January 2022, DreAMLand™ received Breakthrough Device Designation from the FDA. The FDA Breakthrough Designation is granted to novel medical devices that have the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. Blue Notes application for Breakthrough Device Designation was supported by positive usability and preliminary efficacy findings.